隶属于 tulane university (louisiana)
相关临床试验
20
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1834
已完成
16
80.0%
招募中
1
5.0%
终止
2
10.0%
撤回
1
5.0%
暂无批准数据
- Radiopharm Theranostics has appointed Dr. Oliver Sartor, an internationally recognized medical oncologist specializing in prostate cancer and radiopharmaceutical therapies, to its Scientific Advisory Board. - Dr. Sartor currently serves as Director of Radiopharmaceutical Clinical Trials at Mayo Clinic and has led multiple pivotal Phase 3 trials resulting in FDA approvals for radiopharmaceutical therapies. - The appointment strengthens Radiopharm's clinical expertise as the company advances its radiopharmaceutical pipeline, which includes one Phase 2 and three Phase 1 trials across various solid tumor cancers.
- Healthcare experts at PCOC meeting emphasize urgent need to align cancer care with value-based principles, addressing high treatment costs that limit access to life-saving therapies. - Dr. Keith Ferdinand advocates for holistic management of cardiovascular-kidney-metabolic syndrome, integrating social determinants of health into risk assessments and treatment plans. - Canadian study reveals significant variations in supportive care practices for elderly MDS/AML patients, highlighting need for standardized evidence-based guidelines.
